Multiple sclerosis (MS) is a chronic neurological disorder that affects the central nervous system (CNS), which includes the brain and spinal cord. It is categorized as an autoimmune condition in which the immune system mistakenly targets the CNS protective myelin sheath. It is divided into relapsing-remitting, primary progressive, and secondary progressive MS. Progressive form is one of the most incapacitating and disabling varieties of MS, however, it can take many various forms. Progressive MS is a chronic, degenerative neurological disorder that, unlike relapsing-remitting (RR) MS, where symptoms come and go is characterized by a steady and progressive worsening of neurological function over time. There are two types of progressive MS: primary progressive MS (PPMS) and secondary progressive MS (SPMS). PPMS is characterized by a gradual and steady decline in neurological function from the onset of the disease, while SPMS develops after an initial period of RR MS, with symptoms becoming steadily worse over time. The symptoms of progressive MS vary widely and can include mobility issues, spasticity, fatigue, vision problems, and cognitive impairment. There is no cure for progressive MS, but there are treatments that can help manage symptoms and slow the progression of the disease. Pharmacological treatments currently available for progressive MS are intended to reduce the disease's development and enhance patients' quality of life. The most used medications for progressive MS include immunomodulatory and immunosuppressive drugs, as well as monoclonal antibodies and stem cell transplants. These medications target different aspects of the immune system and can help reduce inflammation, demyelination, and neurodegeneration. However, their efficacy varies from patient to patient, and they can also cause significant side effects. Newer therapies are being developed that target specific molecules and pathways involved in MS pathogenesis, with the goal of achieving greater efficacy and fewer side effects.